87 related articles for article (PubMed ID: 1806186)
21. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone.
Alegre ML; Vandenabeele P; Depierreux M; Florquin S; Deschodt-Lanckman M; Flamand V; Moser M; Leo O; Urbain J; Fiers W
J Immunol; 1991 Feb; 146(4):1184-91. PubMed ID: 1825107
[TBL] [Abstract][Full Text] [Related]
22. OKT3-induced cytokine-release syndrome: prevention effect of anti-tumor necrosis factor monoclonal antibody.
Chatenoud L
Transplant Proc; 1993 Apr; 25(2 Suppl 1):47-51. PubMed ID: 8465425
[No Abstract] [Full Text] [Related]
23. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM
Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559
[TBL] [Abstract][Full Text] [Related]
24. Fas cross-linking mimics the inhibitory effect of anti-CD3 on IL-3-induced histamine and cytokine production by murine myeloid spleen cell precursors.
Ben Amor A; Schneider E; Arnould A; Machavoine F; Dy M
Exp Hematol; 1998 Aug; 26(9):903-9. PubMed ID: 9694512
[TBL] [Abstract][Full Text] [Related]
25. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
Le Gall F; Reusch U; Moldenhauer G; Little M; Kipriyanov SM
J Immunol Methods; 2004 Feb; 285(1):111-27. PubMed ID: 14871540
[TBL] [Abstract][Full Text] [Related]
26. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions.
Li B; Wang H; Dai J; Ji J; Qian W; Zhang D; Hou S; Guo Y
Immunology; 2005 Dec; 116(4):487-98. PubMed ID: 16313362
[TBL] [Abstract][Full Text] [Related]
27. Control of T lymphocyte activation and IL-2 receptor expression by endogenously secreted lymphokines.
Pimentel-Muiños FX; Muñoz-Fernández MA; Fresno M
J Immunol; 1994 Jun; 152(12):5714-22. PubMed ID: 8207202
[TBL] [Abstract][Full Text] [Related]
28. The role of endogenous IFN-gamma, TNF-alpha and IL-10 in LPS-induced nitric oxide release in a mouse model.
ter Steege JC; van de Ven MW; Forget PP; Brouckaert P; Buurman WA
Cytokine; 1998 Feb; 10(2):115-23. PubMed ID: 9512901
[TBL] [Abstract][Full Text] [Related]
29. Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines.
Harrop JA; Reddy M; Dede K; Brigham-Burke M; Lyn S; Tan KB; Silverman C; Eichman C; DiPrinzio R; Spampanato J; Porter T; Holmes S; Young PR; Truneh A
J Immunol; 1998 Aug; 161(4):1786-94. PubMed ID: 9712045
[TBL] [Abstract][Full Text] [Related]
30. Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies. Accessory cell-independent induction of interleukin 2 responsiveness in T cells by epsilon-anti-CD3.
van Lier RA; Boot JH; Verhoeven AJ; de Groot ER; Brouwer M; Aarden LA
J Immunol; 1987 Nov; 139(9):2873-9. PubMed ID: 3117878
[TBL] [Abstract][Full Text] [Related]
31. DNA fragmentation and detachment of enterocytes induced by anti-CD3 mAb-activated intraepithelial lymphocytes.
Yaguchi K; Kayaba S; Soga H; Yamagishi M; Tamura A; Kasahara S; Ohara S; Satoh J; Oka Y; Toyota T; Itoh T
Cell Tissue Res; 2004 Jan; 315(1):71-84. PubMed ID: 14579144
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome.
Lay JD; Tsao CJ; Chen JY; Kadin ME; Su IJ
J Clin Invest; 1997 Oct; 100(8):1969-79. PubMed ID: 9329960
[TBL] [Abstract][Full Text] [Related]
33. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
[TBL] [Abstract][Full Text] [Related]
34. Activation of cord T lymphocytes. III. Role of LFA-1/ICAM-1 and CD2/LFA-3 adhesion molecules in CD3-induced proliferative response.
Gerli R; Agea E; Muscat C; Tognellini R; Fiorucci G; Spinozzi F; Cernetti C; Bertotto A
Cell Immunol; 1993 Apr; 148(1):32-47. PubMed ID: 7684326
[TBL] [Abstract][Full Text] [Related]
35. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
Corral LG; Haslett PA; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G
J Immunol; 1999 Jul; 163(1):380-6. PubMed ID: 10384139
[TBL] [Abstract][Full Text] [Related]
36. Selective immunosuppression with anti-T cell monoclonal antibodies.
Chatenoud L; Bach JF
Clin Nephrol; 1992; 38 Suppl 1():S53-60. PubMed ID: 1295709
[TBL] [Abstract][Full Text] [Related]
37. The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation.
Chatenoud L; Ferran C; Bach JF
Curr Top Microbiol Immunol; 1991; 174():121-34. PubMed ID: 1839376
[No Abstract] [Full Text] [Related]
38. Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects.
Kroesen BJ; Janssen RA; Buter J; Nieken J; Sleijfer DT; Mulder NH; De Leij L
J Hematother; 1995 Oct; 4(5):409-14. PubMed ID: 8581377
[TBL] [Abstract][Full Text] [Related]
39. CD3 antibody-induced IL-10 in renal allograft recipients: an in vivo and in vitro analysis.
Herbelin A; Abramowicz D; de Groote D; Naret C; Kreis H; Bach JF; Goldman M; Chatenoud L
Transplantation; 1999 Sep; 68(5):616-22. PubMed ID: 10507478
[TBL] [Abstract][Full Text] [Related]
40. Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids.
Ferran C; Dy M; Merite S; Sheehan K; Schreiber R; Leboulenger F; Landais P; Bluestone J; Bach JF; Chatenoud L
Transplantation; 1990 Oct; 50(4):642-8. PubMed ID: 1699310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
